Jan van de Winkel becomes chair of Hookipa Biotech

Company: Hookipa Biotech AG

Appointee: Jan van de Winkel



The Austria-based biotech company Hookipa Biotech AG has appointed Jan van de Winkel as chairman of its board of directors to help oversee the progress of its early-stage vaccine portfolio. Dr van de Winkel is co-founder and chief executive of the antibody therapeutic developer Genmab A/S. He holds a professorship of immunotherapy at Utrecht University and received both MS and PhD degrees from the University of Nijmegen in the Netherlands.

Hookipa announced the appointment on 18 October 2017.

Copyright 2017 Evernow Publishing Ltd